Ignore The Drama At Valley National Bancorp (VLY), Edwards Lifesciences Corporation (EW)

VLY trading volume has lost -1425248 shares compared to readings over the past three months as it recently exchanged 1294752 shares. This means there is reduced activity from short-term traders as per session, its average trading volume is 2720000 shares, and this is 0.48 times the normal volume. A look at its technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 59.66 point.

Valley National Bancorp (NASDAQ:VLY) dipped by -12.44% over the past three months which led to its overall six-month decrease to stand at -21.01%. The equity price rose 5.57% this week, a trend that has led to both investors and traders taking note of the stock. A look at its monthly performance shows that its shares have recorded a 2.6% gain over the past 30 days. Over the past 12 months the stock has embarked on a drop that has seen it decline -16.6% and is now up by 10.92% since start of this year.

The shares of Valley National Bancorp dropped by -26.38% or -$3.53 from its last recorded high of $13.38 which it attained on December 03 to close at $9.85 per share. Over the past 52 weeks, the shares of Valley National Bancorp has been trading as low as $8.42 before witnessing a massive surge by 16.98% or $1.43. This price movement has led to the VLY stock receiving more attention and has become one to watch out for. It jumped by 0.51% on Sunday and this got the market excited. The stock’s beta now stands at 1.21 and when compared to its 200-day moving average and its 50-day moving average, VLY price stands -14.59% below and 1.01% above respectively. Its average daily volatility for this week is 2.63% which is less than the 3.42% recorded over the past month.

Experts from research firms are bullish about the near-term performance of Valley National Bancorp (VLY) with most of them predicting a $11.4 price target on a short-term (12 months) basis. The average price target by the analysts will see a 15.74% rise in the stock and would lead to VLY’s market cap to surge to $3.76B. The stock has been rated an average 0, which roughly stands towards the bullish end of the spectrum. Reuters looked into the 11 analysts that track Valley National Bancorp (NASDAQ:VLY) and find out that 5 of them rated it as a Hold. 6 of the 6 analysts rated it as a Buy or a Strong Buy while 0 advised investors to desist from buying the stock or sell it if they already possess it.

The price of Edwards Lifesciences Corporation (NYSE:EW) currently stands at $152.8 after it went down by $-2.31 or -1.49% and has found a strong support at $151.18 a share. If the EW price drops below that critical support, then it would lead to a bearish trend. In the short-term, a dip below the $149.56 mark would also be bad for the stock as it means that the stock would plunge by 2.12% from its current position. However, if the stock price is able to trade above the resistance point around $154.46, then it could likely surge higher to try and break the upward resistance which stands at $156.12 a share. Its average daily volatility over the past one month stands at 3.19%. The stock has plunged by 1.03% from its 52-weeks high of $151.22 which it reached on Sep. 28, 2018. In general, it is 23.19% above its 52-weeks lowest point which stands at $117.37 and this setback was observed on Dec. 01, 2018.

The EW stock Stochastic Oscillator (%D) is at 82.17%, which means that it is currently overbought and its prices could dip very soon. The shares P/S ratio stands at 8.92. The stock currently has an estimated price-earnings (P/E) multiple of 29.35, which is lower than the 33.34 multiple of 12-month price-earnings (P/E). The company’s earnings have gone up, with a quarterly increase rate of 27% over the past five years.

Analysts view Edwards Lifesciences Corporation (NYSE:EW) as a Hold, with 2.4 consensus rating. Reuters surveyed 25 analysts that follow EW and found that 9 of those analysts rated the stock as a Hold. The remaining 16 were divided, with 14 analyst rating it as a Buy or a Strong Buy while 2 analysts advised investors to desist from buying Edwards Lifesciences Corporation (EW) shares or sell it if they already own it.